<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="1468-6708-3-10"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
	<note type="other">BioMed Central</note>

	<note type="page">Page 1 of 9<lb/></note>
	<note type="other">(page number not for citation purposes)<lb/></note>

	<note type="other">Current Controlled Trials in<lb/> Cardiovascular Medicine<lb/></note>
	
	<note type="copyright">Open Access<lb/></note>
	
	<reference>Current Controlled Trials in Cardiovascular Medicine<lb/> 2002,<lb/> 3 x<lb/></reference>
	
	<note type="articleType">Research article<lb/></note>

	<docTitle>
	<titlePart>Validation of Heart Failure Events in the Antihypertensive and Lipid<lb/> Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)<lb/> Participants Assigned to Doxazosin and Chlorthalidone<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>Linda B Piller* 1 , Barry R Davis 1 , Jeffrey A Cutler 2 , William C Cushman 3 ,<lb/> Jackson T Wright Jr 4 , Jeff D Williamson 5 , Frans HH Leenen 6 ,<lb/> Paula T Einhorn 2 , Otelio S Randall 7 , John S Golden 8 and L Julian Haywood 9<lb/>
	</docAuthor>
	</byline> 
	
	<note type="other">for the ALLHAT Collaborative Research Group 10<lb/></note>

	<byline>
		<affiliation>Address: 1 The University of Texas School of Public Health,</affiliation>
	</byline>

	<address>Houston, TX, USA,</address>

	<byline>
	<affiliation>2 National Heart, Lung, and Blood Institute,</affiliation>
	</byline>

	<address>Bethesda, MD, USA,<lb/></address>

	<byline>
	<affiliation>3 Memphis Veterans Affairs Medical Center,</affiliation>
	</byline>

	<address>Memphis, TN, USA,</address>

	<byline>
	<affiliation>4 Case Western Reserve University School of Medicine,</affiliation>
	</byline>

	<address>Cleveland, OH, USA,</address>

	<byline>
	<affiliation>5 Wake<lb/> Forest University,</affiliation>
	</byline>

	<address>Winston-Salem, NC, USA,</address>

	<byline>
	<affiliation>6 University of Ottawa Heart Institute,</affiliation>
	</byline>

	<address>Ottawa, ON, Canada,</address>

	<byline>
	<affiliation>7 Howard University Medical School,<lb/></affiliation>
	</byline>

	<address>Washington, DC, USA,</address> 
			
	<byline>
	<affiliation> 8 Kaiser Permanente, Mid-Atlantic States,</affiliation>
	</byline>
	
	<address>Washington, DC, USA,</address>
			
	<byline>
	<affiliation>9 Keck School of Medicine, University of Southern<lb/> California,</affiliation>
	</byline>

	<address>Los Angeles, CA, USA</address>

	<note type="other">and 10 For a complete list of members of the ALLHAT Collaborative Research Group see JAMA 2000; 283:1973–<lb/> 1975<lb/></note>

	<email>E-mail: Linda B Piller* lpiller@sph.uth.tmc.edu; Barry R Davis - bdavis@sph.uth.tmc.edu; Jeffrey A Cutler - CUTLERJ@NHLBI.NIH.GOV;<lb/> 
	William C Cushman - WILLIAM.CUSHMAN@MED.VA.GOV; Jackson T Wright - JXW20@PO.CWRU.EDU;<lb/>
	Jeff D Williamson - JWILLIAM@WFUBMC.EDU; Frans HH Leenen - fleenen@ottawaheart.ca; Paula T Einhorn - einhornp@nhlbi.nih.gov;<lb/>
	Otelio S Randall - osrandall@howard.edu; John S Golden - John.Golden@kp.org; L Julian Haywood - JHAYWOOD@HSC.USC.EDU;<lb/>
	the ALLHAT Collaborative Research Group - bdavis@sph.uth.tmc.edu<lb/></email> 

	<note type="other">*Corresponding author</note>

	<date>Published: 14 November 2002<lb/></date>
	
	<reference>Current Controlled Trials in Cardiovascular Medicine 2002, 3:10<lb/></reference>
	
	<ptr type="web">This article is available from: http://cvm.controlled-trials.com/content/3/1/10<lb/></ptr>
	
	<note type="submission">Received: 23 October 2002 Accepted: 14 November 2002<lb/></note>
	
	<note type="copyright">© 2002 Piller et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted<lb/>
	in all media for any purpose, provided this notice is preserved along with the article&apos;s original URL.<lb/></note>
	
	<keywords>Keywords: heart failure, alpha-blocker, diuretic, clinical trial<lb/></keywords>
	
	<div type="abstract"> Abstract<lb/>
	Background: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial <lb/>
	(ALLHAT) is a randomized, double-blind, active-controlled trial designed to compare the rate of <lb/>
	coronary heart disease events in high-risk hypertensive participants initially randomized to a <lb/>
	diuretic (chlorthalidone) versus each of three alternative antihypertensive drugs: alpha-adrenergic <lb/>
	blocker (doxazosin), ACE-inhibitor (lisinopril), and calcium-channel blocker (amlodipine). <lb/>
	Combined cardiovascular disease risk was significantly increased in the doxazosin arm compared <lb/>
	to the chlorthalidone arm (RR 1.25; 95% CI, 1.17–1.33; P &lt; .001), with a doubling of heart failure <lb/>
	(fatal, hospitalized, or non-hospitalized but treated) (RR 2.04; 95% CI, 1.79–2.32; P &lt; .001). <lb/>
	Questions about heart failure diagnostic criteria led to steps to validate these events further.<lb/>
	
	Methods and Results: Baseline characteristics (age, race, sex, blood pressure) did not differ <lb/>
	significantly between treatment groups (P &lt; .05) for participants with heart failure events. Post-<lb/>
	event pharmacologic management was similar in both groups and generally conformed to accepted <lb/>
	heart failure therapy. Central review of a small sample of cases showed high adherence to ALLHAT <lb/>
	heart failure criteria. Of 105 participants with quantitative ejection fraction measurements <lb/>
	provided, (67% by echocardiogram, 31% by catheterization), 29/46 (63%) from the chlorthalidone <lb/>
	group and 41/59 (70%) from the doxazosin group were at or below 40%. Two-year heart failure <lb/>
	case-fatalities (22% and 19% in the doxazosin and chlorthalidone groups, respectively) were as <lb/>
	expected and did not differ significantly (RR 0.96; 95% CI, 0.67–1.38; P = 0.83).<lb/>
	
	Conclusion: Results of the validation process supported findings of increased heart failure in the <lb/>
	ALLHAT doxazosin treatment arm compared to the chlorthalidone treatment arm.<lb/>
	</div>

		</front>
	</text>
</tei>
